miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy

• Main Authors: Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK
• Format: Article in Journal/Newspaper
• Language: English
• Published: Dove Medical Press 2022
• Subjects: microrna; targeted treatment; apoptosis; sensitize; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282; Arctic; Haugen; Haugland; Kristensen; Norway; Tromsø; Viken; Arctic University of Norway; UiT The Arctic University of Norway
• Online Access: https://doaj.org/article/a894b8e4b1064711bfeb982a97bdaad0

Lisa Svartdal Normann,1– 3 Mads Haugland Haugen,2 Miriam Ragle Aure,3 Vessela N Kristensen,3 Gunhild Mari Mælandsmo,2,4 Kristine Kleivi Sahlberg1,2 1Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway; 2Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; 3Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; 4Institute for Medical Biology, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromsø, NorwayCorrespondence: Kristine Kleivi Sahlberg, Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway, Tel [phone], Email [e-mail]: Human epidermal growth factor receptor 2 positive (HER2+) breast cancers responding poorly to targeted therapy need improved treatment options. miR-101-5p has shown tumor-suppressive properties in multiple cancer forms, and we assessed the effect and mechanism of action of this miRNA in HER2+ breast cancer.Methods: Expression levels of miR-101-5p in two clinical datasets, TCGA and METABRIC, were compared between tumor and normal adjacent samples, and across molecular subtypes and HER2 status. The ability of miR-101-5p to sensitize for treatment with lapatinib, tucatinib and trastuzumab was explored in HER2+ breast cancer cells responding poorly to such targeted drugs. Proliferation and apoptosis assays and downstream protein analysis were performed.Results: Expression levels of miR-101-5p were significantly lower in tumor compared to normal adjacent tissue (p < 0.001), and particularly low in HER2+ tumors, both the HER2-enriched subtype (p ≤ 0.037) and clinical HER2-status (p < 0.001). In a HER2+ cell line (KPL4) responding poorly to targeted drugs, miR-101-5p overexpression inhibited proliferation (p < 0.001), and combinatorial treatment with lapatinib and trastuzumab significantly further decreased this inhibition (p = 0.004). ...